Market capitalization | $21.23b |
Enterprise Value | $23.75b |
P/E (TTM) P/E ratio | 59.38 |
EV/FCF (TTM) EV/FCF | 125.53 |
EV/Sales (TTM) EV/Sales | 6.24 |
P/S ratio (TTM) P/S ratio | 5.58 |
P/B ratio (TTM) P/B ratio | 2.68 |
Dividend yield | 0.01% |
Last dividend (FY23) | $0.02 |
As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.
20 Analysts have issued a Cooper Cos forecast:
20 Analysts have issued a Cooper Cos forecast:
Jul '24 |
+/-
%
|
||
Revenue | 3,804 3,804 |
8%
8%
|
|
Gross Profit | 2,327 2,327 |
10%
10%
|
|
EBITDA | 1,060 1,060 |
17%
17%
|
EBIT (Operating Income) EBIT | 643 643 |
26%
26%
|
Net Profit | 359 359 |
31%
31%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
The Cooper Cos, Inc. operates as a medical device company. It operates through the following business units: Cooper Vision and Cooper Surgical. The Cooper Vision business unit brings a refreshing perspective on vision care with a commitment to crafting quality lenses for contact lens wearers. The Cooper Surgical business unit focuses on supplying women's health clinicians with market medical products and treatment options to improve the delivery of healthcare to women. The company was founded in 1958 and is headquartered in San Ramon, CA.
Head office | United States |
CEO | Albert White |
Employees | 15,000 |
Founded | 1958 |
Website | www.coopercos.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.